AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Disintegrin and metalloproteinase domain-containing protein 10

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O14672

UPID:

ADA10_HUMAN

Alternative names:

CDw156; Kuzbanian protein homolog; Mammalian disintegrin-metalloprotease

Alternative UPACC:

O14672; B4DU28; Q10742; Q92650

Background:

Disintegrin and metalloproteinase domain-containing protein 10, also known as ADAM10, plays a pivotal role in cellular processes including proteolytic release of cell-surface proteins and cleavage of amyloid precursor protein (APP). Its activity is crucial for the development and maturation of various tissues, including the vasculature and the nervous system. ADAM10's involvement in cleaving cell adhesion molecules and cytokine receptors underscores its multifaceted role in biological systems.

Therapeutic significance:

ADAM10's link to diseases such as Reticulate acropigmentation of Kitamura and Alzheimer disease 18 highlights its potential as a therapeutic target. Its role in the proteolytic processing of APP and contribution to the amyloidogenic pathway suggest that modulating ADAM10 activity could offer new avenues for treating Alzheimer's disease. Understanding the role of ADAM10 could open doors to potential therapeutic strategies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.